Tesamorelin Research for Body Composition
An evidence-based overview of research examining Tesamorelin in the context of body composition. This page synthesizes findings from peer-reviewed literature.
Research Summary
The pivotal HIV trials measured less VAT and modestly higher lean body mass at week 26. The FDA label reports lean-mass changes of +1.3 and +1.2 kg in the two tesamorelin arms versus -0.2 and -0.03 kg with placebo. Body weight remained approximately neutral; EGRIFTA WR is not indicated for weight management. A 2026 meta-analysis pooled overlapping trials, so its participant count must not be added to the pivotal studies. Clinical outcomes from the lean-mass change remain uncertain.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Always consult a healthcare provider before making health decisions.